Osimertinib as 1st Line Therapy for Patients With Advanced EGFR Positive Non-Small Cell Lung Cancer

Hellenic Cooperative Oncology Group

Status: Enrolling

Conditions: Lung Cancer Non-small Cell Stage IV

Study type: Observational

Funder types: Other

Identifiers

NCT05127382

HE219

Details and patient eligibility

About

The present study will evaluate the use of osimertinib as 1st line therapy for patients with advanced EGFR positive non-small cell lung cancer who are treated at Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology.

Full description

This will be an observational, multicentric, retrospective/ prospective analysis of patients with advanced EGFR positive non-small cell lung cancer that receive osimertinib as 1st line therapy. The patient data will be collected at Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology during scheduled patient clinical visits, from February 2020 for a total period of three years. The biological material obtained from the patients of this analysis will be possibly used in a future translational study as an exploratory analysis.

Enrollment: 40 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• men or women of 18 years or older that live in Greece
• histologically or cytologically confirmed, advanced EGFR positive non-small cell lung cancer
• untreated patients for advanced NSCLC
• patients who are expected to receive osimertinib regardless of their enrollment in the study
• signed written informed consent

Exclusion criteria

• patients with cancer other than NSCLC that require treatment
• pretreated patients for NSCLC
• patients that receive or are expected to receive or have received an investigational drug/product/intervention

Trial design

40 participants in 1 patient group

untreated patients with advanced EGFR positive non-small cell lung cancer